Alphadyne Asset Management’s Biogen BIIB Stock Holding History

Alphadyne Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,218	Closed	-$223K	–	901
2026 Q1	$223K	Buy	+1,218	New	+$224K	﹤0.01%	785

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Alphadyne Asset Management's BIIB Position: Q2 2026 in Review

Alphadyne Asset Management sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,218 shares — an estimated $223K sold.

Alphadyne Asset Management first reported a position in BIIB in Q1 2026 and held it in 1 quarter. The position peaked at $223K in Q1 2026. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Alphadyne Asset Management reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Alphadyne Asset Management sold 1,218 Biogen shares in Q2 2026, an estimated $223K.
Alphadyne Asset Management first reported a position in Biogen in Q1 2026 and held it in 1 quarter.
Alphadyne Asset Management's Biogen position peaked at $223K in Q1 2026.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Alphadyne Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.